论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Shen X, Tao Y, Yang Y, Wang R, Fang J, Lian M
Received 27 August 2018
Accepted for publication 30 November 2018
Published 31 December 2018 Volume 2019:12 Pages 341—348
DOI https://doi.org/10.2147/OTT.S185428
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 3
Editor who approved publication: Dr Federico Perche
Background: Hypopharyngeal
squamous cell carcinoma and laryngeal squamous cell carcinoma have a potential
risk of metastasis and local recurrence. It is urgent to determine novel
effective therapy.
Methods: UMSCC5
and FADU cells were treated with TPF regimen (a mixture comprising paclitaxel,
cisplatin, and 5-fluorouracil), cinobufotalin, and combination. Cell counting
kit-8 (CCK-8), clone formation assays, and flow cytometry were performed to
investigate whether combination of cinobufotalin and TPF can exhibit
synergistic effects in reducing tumor growth.
Results: CCK-8
assay and IC50 analysis showed that the TPF and
cinobufotalin could suppress viability of UMSCC5 and FADU cells, implying the
strong antitumor effect. The synergism between TPF and cinobufotalin was
further verified by the CCK-8 and clone formation assays showing the TPF- and
cinobufotalin-suppressed cell proliferation synergistically. Notably, flow
cytometry showed that the combination also promoted apoptosis synergistically.
Conclusion: TPF
regimen combining cinobufotalin suppressed proliferation and promoted apoptosis
synergistically in hypopharyngeal squamous cell carcinoma and laryngeal
squamous cell carcinoma cells.
Keywords: TPF
regimen, cinobufotalin, hypopharyngeal and laryngeal squamous cell carcinoma,
proliferation, apoptosis